The complement molecules C3 and C4 have been previously associated with cancer progression and activation of PI3K signaling[41], whereas C5a is suspected to inhibit CD8 lymphocytes and natural killer (NK) cells, a subset of immune cells involved in the immune response towards tumors [42]. This evidence concerns the gene C5 and cancer.